Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00044798 · ClinicalTrials.gov registry record · Phase 3

Magnetic Stimulation Therapy for Treating Vascular Depression

A Phase 3 study of Depression and Depressive Disorder, sponsored by University of Iowa.

Completed
Registry status
Phase 3
Development phase
132
Enrollment target
1
Study location

NCT00044798 is a Phase 3 study of Depression and Depressive Disorder that has completed, run by University of Iowa. The registered enrollment target is 132 participants, below the 786-participant average among 679 other Depression trials with a reported enrollment target (83% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00044798, a Phase 3 study of Depression and Depressive Disorder, has completed, sponsored by University of Iowa.

COMPLETED
Registry status
Phase 3
Development phase
132 participants
Enrollment target
1
Study location

Study Summary

This 12-week study will evaluate the effectiveness of repetitive transcranial magnetic stimulation (rTMS) of the brain, followed by citalopram (Celexa®), for treatment of depression associated with small vascular lesions in the brain (vascular depression).

Interventions

  • DRUG Citalopram
  • PROCEDURE Repetitive transcranial magnetic stimulation (rTMS)
  • PROCEDURE Sham rTMS

Study Locations (1)

Iowa

  • University of Iowa Health Care - Iowa City

Trial Details

FieldValue
Enrollment Target 132 participants
Start Date 2001-09
Est. Completion 2008-08
Phase Phase 3

Sponsor

University of Iowa

228 total trials

What the Registry Record Tells You About NCT00044798

The ClinicalTrials.gov registry entry for NCT00044798 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 132 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 786-participant average among 679 other Depression trials with a reported enrollment target (83% lower). The listed sponsor is University of Iowa, which has 228 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Depression appearing as the primary indexed condition, and to 3 interventions - of which Citalopram is the first listed.

NCT00044798 reports 1 study location spanning 1 distinct geographic area - top geographies include Iowa.

Frequently Asked Questions

What is clinical trial NCT00044798 about?

NCT00044798 is a clinical study titled "Magnetic Stimulation Therapy for Treating Vascular Depression". This 12-week study will evaluate the effectiveness of repetitive transcranial magnetic stimulation (rTMS) of the brain, followed by citalopram (Celexa®), for treatment of depression associated with small vascular lesions in the brain (vascular depression).

What is the current status of trial NCT00044798?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 132 participants. The study started on 2001-09. Estimated completion is 2008-08.

What conditions does trial NCT00044798 study?

This clinical trial studies the following conditions: Depression, Depressive Disorder.

What interventions are being tested in trial NCT00044798?

The interventions under investigation include: Citalopram (DRUG), Repetitive transcranial magnetic stimulation (rTMS) (PROCEDURE), Sham rTMS (PROCEDURE).

Who is sponsoring clinical trial NCT00044798?

This trial is sponsored by University of Iowa, which has 228 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00044798 being conducted?

This trial has 1 study location across Iowa. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Depression

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.